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Exome Sequencing Identifies
GNB4 Mutations as a Cause of Dominant
Intermediate Charcot-Marie-Tooth Disease
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Charcot-Marie-Tooth disease (CMT) is a heterogeneous group of inherited neuropathies. Mutations in approximately 45 genes have
been identified as being associated with CMT. Nevertheless, the genetic etiologies of at least 30% of CMTs have yet to be elucidated.
Using a genome-wide linkage study, we previously mapped a dominant intermediate CMT to chromosomal region 3q28–q29. Subse-
quent exome sequencing of two affected first cousins revealed heterozygous mutation c.158G>A (p.Gly53Asp) in GNB4, encoding
guanine-nucleotide-binding protein subunit beta-4 (Gb4), to cosegregate with the CMT phenotype in the family. Further analysis of
GNB4 in an additional 88 unrelated CMT individuals uncovered another de novo mutation, c.265A>G (p.Lys89Glu), in this gene in
one individual. Immunohistochemistry studies revealed that Gb4 was abundant in the axons and Schwann cells of peripheral nerves
and that expression of Gb4 was significantly reduced in the sural nerve of the two individuals carrying the c.158G>A (p.Gly53Asp) muta-
tion. In vitro studies demonstrated that both the p.Gly53Asp and p.Lys89Glu altered proteins impaired bradykinin-induced G-protein-
coupled-receptor (GPCR) signaling, which was facilitated by the wild-type Gb4. This study identifies GNB4mutations as a cause of CMT
and highlights the importance of Gb4-related GPCR signaling in peripheral-nerve function in humans.Charcot-Marie-Tooth disease (CMT) is a group of inherited
neuropathies characterized by progressive distal muscle
atrophy, distal sensory loss, depressed tendon reflexes,
and foot deformities; they can be categorized into either
the demyelinating form or the axonal form by their elec-
trophysiological and pathological features.1,2 Clinically,
median motor nerve conduction velocity (NCV) is the
most frequent parameter (with a cutoff value of 38 m/s)
used for distinguishing between demyelinating and axonal
CMT.3 Mutations in approximately 45 genes have been
identified as being associated with CMT, but these account
for fewer than 70% of all CMT cases.1,2 Within the CMTs,
dominant intermediate CMT (DI-CMT) is a rare group
that shows autosomal-dominant inheritance and variable
NCVs, which can look like either demyelinating or axonal
types of CMT within a pedigree.3–6 Previously, we charac-
terized a three-generation Chinese family afflicted with
a DI-CMT and mapped the locus of the candidate gene to
chromosomal region 3q28–q29.7 In this study, 13 family
members, including six affected individuals, five unaf-
fected individuals, and two married-in spouses, were
enrolled (Figure 1A). Disease status was determined by
both the clinical manifestations and electrophysiological
evidence.3 In brief, the age of onset ranged from 10 to 45
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median motor NCVs ranged from 16.5 to 45.7 m/s. Men
tended to be more severely affected (Table 1). Sural nerve
biopsies of two affected individuals detected loss of
myelinated fibers and also demyelinating changes as
evidenced by multiple onion-bulb formations. Written
informed consent was obtained from all subjects, and the
study protocol was approved by the institutional review
board at Taipei Veterans General Hospital, Taipei, Taiwan.
Genomic DNA was isolated from peripheral-blood leuko-
cytes according to standard protocol.
About 165,000 exonic regions from the genomic DNA of
the two affected first cousins of family 1 (IV-1 and IV-4 in
Figure 1A) were captured and enriched with the Agilent
SureSelect Human All Exon v.2 kit. The DNA-sequencing
libraries were prepared with an Illumina Paired-End DNA
Sample Preparation kit. A total of 100 bp paired-end reads
were obtained by sequencing on an Illumina Genome
Analyzer GAIIx. All sequence reads were mapped to the
human reference genome (GRCh37 patch 2) with the
Burrows-Wheeler Aligner.8 Removal of PCR duplicates
and variant calling were performed with SAMtools/
BCFTools.9 Only the variants with Phred-like scores of at
least 30.0 were collected for the investigation of candidate
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Figure 1. Pedigrees and Electrophero-
grams of the GNB4 Mutations
(A and B) Pedigree structure of families 1
(A) and 2 (B). The probands are denoted
by an arrow. The squares and circles
denote males and females, respectively,
and the diagonal black lines represent
deceased individuals. Filled symbols repre-
sent affected members with neuropathy,
and open symbols indicate unaffected
individuals. The numbers in diamonds
indicate the number of unaffected siblings
or children. The gender and birth order
have been partially hidden for the sake of
confidentiality. ‘‘M’’ represents the GNB4
mutant allele, ‘‘W’’ stands for the wild-
type allele, and asterisks denote members
who underwent whole-exome sequencing.
(C) The electropherograms of the hetero-
zygous GNB4 mutations, c.158G>A
(p.Gly53Asp) and c.265A>G (p.Lys89Glu).
(D) RT-PCR analysis of the RNA isolated
from the leukocytes of a normal control
and the individual carrying GNB4
c.265A>G with the use of primers specific
to GNB4 exons 5 and 6. Both samples re-
vealed a single band at the same location
(218 bp), indicating that GNB4 mRNA
from the affected individual was not differ-
entially spliced.
(E) The cDNA electropherograms of the
GNB4 exon 5 and 6 junction of a normal
control and the affected individual
carrying GNB4 c.265A>G reveal similar
splicing patterns.was generated from each individual, resulting in a coverage
depth of 833 per base per targeted region. After analysis
(Table S1, available online), 64 heterozygous coding vari-
ants were found in both individuals; these variants were
not present in dbSNP, the 1000 Genomes Project,10 or
the in-house exome data from ten non-CMT ethnic
controls. Targeted sequencing of eleven other members
of family 1 revealed that only the c.158G>A (p.Gly53Asp)
variant in GNB4 (MIM 610863; RefSeq accession number
NM_021629.3), encoding guanine-nucleotide-binding
protein (G protein) subunit beta-4 (Gb4), perfectly segre-
gated with the CMT phenotype (Figures 1A and 1C). This
variant was also located within the chromosomal region
3q28-q29, which was the previously mapped locus for
this type of CMT.
To support that mutations in GNB4 cause CMT and to
investigate the frequency of GNB4 mutations in our CMT
population, we further sequenced all nine coding exons
of GNB4 in another 88 unrelated individuals with molecu-
larly unassigned CMT (Table S2); these individuals
included 66 with the demyelinating variant and 22 with
the axonal variant. Among them, one additional de novoThe American Journal of Humanmutation, c.265A>G (p.Lys89Glu)
(Figures 1B and 1C) in the heterozy-
gous form, was identified. Neither
the GNB4 c.158G>A mutation northe c.265A>G mutation was present in the Exome
Variant Server of the National Heart, Lung, and Blood Insti-
tute (NHLBI) Exome Sequencing Project or in 1,920 ethni-
cally matched control chromosomes. Gly53 and Lys89 are
highly conserved residues in Gb4 (Figure S1). SNPs&GO,11
Panther,12 and Polyphen213 predicted both mutations to
be deleterious to Gb4 functioning
14 (Table S3). Because
the c.265A>G mutation occurs at the nucleotide adjacent
to the exon-intron boundary (Figure 1C), we analyzed the
mRNA from leukocytes of the individual carrying this
mutation by RT-PCR and nucleotide sequencing. No
splicing alteration was found (Figures 1D and 1E). We
also utilized a minigene assay to demonstrate that the
GNB4 c.265A>G mutation did not change the mRNA
splicing pattern (Figure S2). Because the CMT individuals
in this study were selected from 251 pedigrees affected by
CMT after the cases with clear genetic diagnosis were
excluded,15 the frequency of GNB4 mutations in our
CMT population was approximately 0.8% (2/251).
The GNB4 c.265A>G (p.Lys89Glu) mutation was found
in a 9-year-old girl who had presented with slowly progres-
sive weakness of her distal lower limbs since the age ofGenetics 92, 422–430, March 7, 2013 423
Table 1. Clinical Features of the Individuals with GNB4 Mutations
Family 1 (c.158G>A [p.Gly53Asp])
Family 2 (c.265A>G
[p.Lys89Glu])
III-2 III-3 IV-1 IV-2 IV-3 IV-4 II-1
Age of onset (years) 13 45 10 13 17 22 5
Age at exam (years) 49 48 23 18 17 22 9
Gender male female male male female female female
Upper-limb weakness (MRC) distal: 4 normal normal normal normal normal normal
Lower-limb weakness (MRC) distal: 2 distal: 4- to 4 distal: 4- to 4 distal: 4 distal: 4þ distal: 4þ distal: 4
Upper-limb muscle atrophy distal: moderate normal distal: mild normal normal normal normal
Lower-limb muscle atrophy distal: severe distal: mild distal: severe distal: mild distal: mild distal: mild distal: moderate





steppage steppage steppage normal normal steppage
Pinprick sensation reduced mildly reduced mildly reduced mildly reduced normal normal mildly reduced
Vibration reduced mildly reduced mildly reduced mildly reduced normal normal mildly reduced
Median nerve MNCV (m/s) 25.2 35.4 16.5 28.6 44.2 45.7 20
Median nerve cMAP (mV) 7.7 8.3 3.9 3.2 9.3 5.9 2.6
Sural nerve SNAP NR NR NR NR NR 7 NR
Sural nerve biopsy demyelination demyelination ND ND ND ND ND
The following abbreviations are used: MRC,Medical Research Council scale; DTR, deep tendon reflex; MNCV, motor nerve conduction velocity; cMAP, compound
motor action potential; SNAP, sensory nerve action potential; NR, not recordable; and ND, not done.5 years. She had started to walk at a normal age. Physical
examination at age 9 years revealed high-arched feet,
hammer toes, atrophy and weakness of the intrinsic
muscles of the feet (score 4/5 on the Medical Research
Council Scale), impaired dorsiflexion of the feet (score
4/5), generalized areflexia, and mildly diminished sensa-
tion for all modalities in regions distal to the ankles despite
a lack of sensory complaints. Nerve conduction studies
demonstrated the presence of demyelinating sensorimotor
polyneuropathy with axonal loss. The median and tibial
motor NCVs were 20 and 15 m/s, respectively. Neither
parent had the CMT phenotype or the GNB4 c.265A>G
mutation (Figure 1B).
G proteins are heterotrimeric and are composed of a, b,
and g subunits; they are important to cellular signal
transduction. They transmit extracellular signals into cells
by acting in concert with different G-protein-coupled
receptors (GPCRs); these GPCRs can be activated by
many different signal factors, such as neurotransmitters,
hormones, and cytokines.16 In humans, there are 16 Ga
subunits, 5 Gb subunits, 12 Gg subunits, and a number
of splice variants, which thus contribute to a large diversity
of G protein heterotrimers.17 In the inactive state, the
guanosine-diphosphate (GDP)-bound Ga is associated
with the Gbg dimer. When a GPCR is activated by a ligand,
it catalyzes the G protein to exchange the GDP for guano-
sine triphosphate (GTP) on Ga, which results in the disso-
ciation of the Ga from the Gbg.16 The Ga-GTP and released424 The American Journal of Human Genetics 92, 422–430, March 7Gbg dimer each then transduce signals to a wide range of
effectors, including adenylyl cyclases, phospholipases,
ion channels, phosphodiesterases, and many more pro-
teins,17,18 thereby regulating various intracellular signaling
pathways and cellular functions. As a result of this wide
range of G protein signaling activities, GNB4, which
encodes Gb4, is likely to be important to a number of
cellular signal-transduction systems.
To understand the location of Gb4 in peripheral nerves,
we analyzed the sural nerves of one neurologically normal
control and one individual (III:3 in Figure 1A) with the
c.158G>A (p.Gly53Asp) GNB4mutation by double immu-
nofluorescence staining. Gb4 was found to be colocalized
with neurofilament heavy chain and S100 (Figure 2 and
Table S4), indicating that Gb4 is expressed in both axons
and Schwann cells. Intriguingly, some myelinated fibers
of the normal control had a target-like appearance because
of the presence of dense Gb4 staining in the axons and the
outer rim of the myelin, but not in the compacted myelin
sheath (Figure 2). Onion-bulb formations in the sural
nerve of individual III:3 showed a ‘‘rosette’’ pattern with
Gb4 staining in the axons and the cytoplasm of sur-
rounding Schwann cells (Figure 2).
We next compared Gb4 expression in the sural nerve
samples from two individuals (III:2 and III:3) with the
GNB4 c.158G>A (p.Gly53Asp) mutation, one individual
with CMT1A, and one neurologically normal control
by immunohistochemistry (IHC). In addition to staining, 2013
Figure 2. Gb4 Expression in Both Axons and Schwann Cells of
Peripheral Nerves
Double immunostaining of Gb4 with neurofilament heavy chain
(NF-H) (A) or S100 (B) with sural nerve samples from a neurologi-
cally normal control and family 1 individual III:3, who harbors the
GNB4 c.158G>A (p.Gly53Asp) mutation. The colocalization of
Gb4 with NF-H and S100 indicates that Gb4 is expressed in both
axons and Schwann cells. Some myelinated fibers of the normal
control have a target-like appearance as a result of dense Gb4 stain-
ing in the axons and the outer rim of the myelin, but not in the
compacted myelin sheath (arrows). Onion-bulb formations in
the sural nerve of individual III:3 have a ‘‘rosette’’ pattern with
Gb4 staining in the axons and the cytoplasm of surrounding
Schwann cells (arrowheads). The scale bars represent 10 um.Gb4, we also doubly stained the cell nuclei with TDP-43
antibody as a reference (Table S4). Immunostaining re-
vealed that Gb4 was abundantly expressed in the axons
and Schwann cells of the sural nerve of the normal control
(Figure 3A). Some myelinated fibers had a target-like
appearance (Figure 3A). Onion-bulb formations in the
sural nerve of the CMT1A control were also densely stained
with Gb4 antibody (Figure 3B). In contrast, Gb4 staining
was significantly weaker in the sural nerves of the two indi-
viduals with the GNB4 mutation than in those of the
normal control and the individual with CMT1A (Figures
3C and 3D).
To test the hypothesis that GNB4 is important for
peripheral nerve functioning, we investigated Gb4 expres-
sion in the sciatic nerves of the rats 3 days after sciatic
nerve transection, nerve conditioning with a 20 s transientThe Amecrush injury, or a sham operation. The nerve tissue 10 mm
in length and distal to the injured site was analyzed for Gb4
expression by immunoblotting and IHC. Compared with
Gb4 expression in the sham-operated group, the expres-
sion of Gb4 appeared to increase in the nerve conditioning
group and decrease in the nerve transection group (Fig-
ure S3). These findings suggest that GNB4 plays a role in
peripheral nerve regeneration and support its importance
in peripheral nerve functioning.
To investigate the effect of the GNB4 mutations on
protein stability and G-protein-coupled signaling by Gb4,
we constructed Gb4 expression plasmids to allow further
in vitro analysis. The coding region of GNB4 from a
human GNB4 cDNA clone (Invitrogen; GenBank accession
number AF300648.1) was subcloned into pcDNA3.1þ
(Invitrogen). Mutations c.158G>A (p.Gly53Asp) and
c.265A>G (p.Lys89Glu) were introduced by site-directed
mutagenesis according to the Quick-Change method
(Stratagene) (Table S5). pECFP-C1 was purchased from
Clontech. A human PLCb2 expression clone, pCMV5-
PLCb2, was a kind gift from E.M. Ross (Southwestern
Medical Center, University of Texas, TX, USA). All con-
structs were verified by DNA sequencing.
In order to carry out a protein-stability assay, we incu-
bated human embryonic kidney (HEK) 293T cells main-
tained in Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone) containing 10% fetal bovine serum (FBS;
Invitrogen) at 37C and in 5% CO2 and transfected
them with plasmids expressing wild-type, p.Gly53Asp, or
p.Lys89Glu forms of Gb4 by using calcium-phosphate
precipitation.19 At 48 hr after transfection, the cells were
treated with 100 mg/ml cyclohexamide for 0, 2, 4, 8, or
24 hr. Total-protein cell extracts were analyzed by immu-
noblotting (40 mg of protein was loaded from each cell
lysate). The immunoblot signals were used for comparing
the relative degradation profiles between the Gb4 variants
and actin. Representative graphs and quantification ob-
tained from six independent experiments are shown in
Figure S4. These results show that the degradation rates
of the two altered forms of Gb4 were not significantly
different from that of their wild-type counterpart, suggest-
ing that these alterations did not affect protein stability.
We next investigated the functional impact of the Gb4
alterations on GPCR signaling. In this functional study,
we used bradykinin to activate the B2-receptor-coupled
Gqa signaling pathway in a PLCb2-overexpressing COS-7
cell model.20,21 Activation of PLCb2 by Gqa signaling leads
tohydrolysis of phosphatidylinositol 4,5-bisphosphate and
the formation of the second messengers inositol trisphos-
phate (IP3) and diacylglycerol, which is followed by IP3-
induced intracellular Ca2þ release. Thus, IP3 production
and cytosolic calcium changes were used to reflect GPCR
signaling activity. In brief, COS-7 cells were maintained in
DMEM containing 10% FBS at 37C and in 5% CO2;
LipofectAmine-2000 (Invitrogen) was used for transfecting
these cells at a 1:1:1 ratiowithplasmids expressing ECFP, ex-
pressing PLCb2, and expressing wild-type, p.Gly53Asp, orrican Journal of Human Genetics 92, 422–430, March 7, 2013 425
Figure 3. Gb4 Immunohistochemistry
and Toluidine-Blue Staining of Sural
Nerves
Double immunostaining of Gb4 (red) and
TDP-43 (dark blue) in sural nerve samples
from a neurologically normal control (A),
a disease control with CMT type 1A
(CMT1A) (B), and family 1 individuals
III:2 (C) and III:3 (D), who harbor the
GNB4 c.158G>A (p.Gly53Asp) mutation.
Some myelinated fibers in the normal
control feature a target-like appearance
(A, arrows). The Gb4 staining of onion-
bulb formations appears weaker in the
two subjects with the GNB4 mutation
(C and D, arrowheads) than in the indi-
vidual with CMT1A (B, arrowheads). The
sural nerves of the two individuals with
theGNB4mutation have obviously weaker
Gb4 staining than do those in the normal
control and the individual with CMT1A.
The cell nuclei were stained with TDP-43
antibody as a reference. The toluidine-
blue staining of sural nerve samples of
individuals III:2 and III:3 from family 1
reveals a loss of myelinated fibers and
a presence of multiple onion-bulb forma-
tions (C and D), associated with a demye-
linating change. The scale bars represent
10 um.p.Lys89Glu forms of Gb4 or empty vectors. Forty-eight
hours after transfection, the cells were harvested for subse-
quent second-messenger analysis. To measure IP3 produc-
tion,wesubcultured thecells intoa96-wellplate at adensity
of 23 104 cells per well with 20 ml PBS. The cells were then
stimulated with 100 nM bradykinin for 1 min and lysed
with 0.2 N perchloric acid. Intracellular IP3 production
was then measured with a HitHunter IP3 Fluorescence
Polarization Assay Kit (DiscoveRx) as outlined in themanu-
facturer’s manual. To measure cytosolic calcium changes,
we incubated cells on coverslips with 5 mM of the calcium
indicator dye fura-2 AM (Molecular Probes) in loading
buffer (LB) for 45 min at 37C and then washed them
with LB. Cells coexpressing ECFP with a similar expression
level (mean pixel intensity ¼ 526.6 5 32.8 AU; n ¼ 148)
were selected for the subsequentmeasurements. These cells
were stimulated with a pulse of 100 nM bradykinin for 10 s
while the fluorescence of fura-2 was simultaneously moni-
tored under an inverted microscope (IX-71, Olympus
Optical) coupled with a monochromator (Polychrome IV,
TILL Photonics, Gra¨felfing, Germany) with a 403 oil-
immersion objective (UApo/340 403/1.35 numeric aper-
ture oil objective, Olympus Optical).22 Use of the 340/
380 nm excitation ratio with fura-2 allowed measurements
of the intracellular calcium concentration ([Ca2þ]i).
23,24
The study revealed that the function of both the
p.Gly53Asp and p.Lys89Glu altered forms of Gb4 was426 The American Journal of Human Genetics 92, 422–430, March 7, 2013impaired, that is, they showed
reduced bradykinin-induced PLCb2
activation, namely an inhibition ofIP3 production and a lower increase in cytosolic calcium.
Compared to control cells, PLCb2-overexpressing cells
showed a bradykinin-induced increase in IP3 production
by 25% (25.7% 5 6.2%, n ¼ 3). When cells coexpressed
wild-type Gb4 and PLCb2, their IP3 generation was found
to be about 3.5-fold higher than that of the PLCb2-
overexpressing cells (87.9 5 11.1% versus 25.7% 5
6.2%). However, compared to the control, the p.Gly53Asp
and p.Lys89Glu altered forms of Gb4 reduced bradykinin-
induced IP3 production by 42.1% 5 2.8% and 45.7% 5
6.0%, respectively (Figure 4A). Similar results were ob-
served when the bradykinin-induced [Ca2þ]i increases
were monitored. Bradykinin induced a similar increase in
[Ca2þ]i when the controls, the PLCb2-overexpressing cells,
and the cells coexpressing PLCb2 and wild-type Gb4 were
compared. However, when the cells coexpressing either
PLCb2 and p.Gly53Asp Gb4 or PLCb2 and p.Lys89Glu
Gb4 were examined, there were no significant changes in
[Ca2þ]i upon bradykinin stimulation (Figures 4B and 4C).
These findings indicate that the mutations in GNB4 cause
a defect in the GPCR signaling cascade and impair the
activation of PLCb2.
Utilizing exome sequencing, bioinformatic analysis, and
mutational analysis, we have identified twomutations that
affect Gb4-encoding GNB4 and are present in subjects
with CMT. Both GNB4 mutations alter the evolutionarily
conserved amino acid residues, are absent from the NHLBI
Figure 4. Inhibition of the GPCR Signaling Results from GNB4
Mutations
(A) The p.Gly53Asp and p.Lys89Glu altered forms of Gb4 had an
inhibition of inositol trisphosphate (IP3) production upon brady-
kinin stimulation. COS-7 cells were transfected with pcDNA3.1
(control, first bar on the left), pcDNA3.1-PLCb2 alone, or
pcDNA3.1-PLCb2 and pcDNA3.1-Gb4 or altered forms of Gb4.
The IP3 generated upon stimulation with 100 nM bradykinin for
1 min was then measured. The IP3 production level was normal-
ized against the control as 100%. The data shown are the
mean5 SEM from three independent transfections.
(B) Absence of changes in intracellular calcium ([Ca2þ]i) upon
bradykinin stimulation in the cells expressing altered forms of
Gb4. COS-7 cells were transfected with pcDNA3.1 (control),
pcDNA3.1-PLCb2 alone, or pcDNA3.1-PLCb2 and pcDNA3.1-Gb4
or altered forms of Gb4 in conjunction with pECFP-C1. Changes
in the F340/F380 ratio of fura-2 upon 100 nM bradykinin stimula-
tion were monitored by a fluorescence microscope. Bradykinin
stimulation started at 30 s and lasted for 10 s. The [Ca2þ]i changes
are shown as the F340/F380 ratio of fura-2 fluorescence.
(C) Maximal [Ca2þ]i changes upon bradykinin stimulation. The
maximal [Ca2þ]i changes were obtained by subtraction of the aver-
aged fluorescence ratio in the 10 s before stimulation from the
maximal fluorescence ratio. The data shown are the mean 5
SEM from 26–34 cells for each group (148 cells in total). The cells
were obtained from at least three independent transfections.
The AmeExome Variant Server, and do not occur in 1,920 ethnic
control chromosomes. Immunohistochemical studies re-
vealed that Gb4 is abundantly expressed in peripheral
nerves, including both axons and Schwann cells. In vitro
studies demonstrated that both GNB4 mutations impair
bradykinin-induced GPCR signaling. Our findings provide
strong genetic and functional evidence supporting that
mutations in GNB4 are the cause of this type of CMT.
According to the tissue expression databases of
UniGene25 and GeneNote (now retired),26 Gb4 is widely
expressed in many human tissues, including the spinal
cord and peripheral nerves. Gb4 has also been found to
be expressed in peripheral nerve myelin by proteome anal-
yses.27 We have been able to consistently demonstrate that
Gb4 is readily detected in the axons and Schwann cells of
sural nerves, which indicates that the Gb4 signal pathway
is essential for peripheral nerve functioning. Decreased
Gb4 immunostaining in the sural nerves of the two CMT
individuals with GNB4 mutations further highlights the
important role of Gb4 dysfunction in the pathogenesis of
this hereditary neuropathy.
Our functional studies have shown that both the
p.Gly53Asp and p.Lys89Glu Gb4 alterations impair GPCR
signaling pathways via a dominant-negative effect. When
compared to cells expressing PLCb2 alone, cells coexpress-
ing PLCb2 and p.Gly53Asp or p.Lys89Glu altered Gb4
showed a significantly reduced IP3 production and an
absence of cytosolic calcium change when stimulated
with bradykinin. This phenomenon suggests that both
altered forms of Gb4 have a negative effect on the endoge-
nous wild-type Gb4 molecules already present in the cells
and that this affects GPCR signaling. Gly53 and Lys89
are highly conserved across the Gb protein family (in-
cluding Gb1–Gb5) across the various kingdoms (including
mammals, fungi, nematode, and amoeba). This suggests
that they both most likely play critical roles in GPCR
signaling.28
The functional defect caused by the two mutations
appears to be related to their roles in the specific binding
of Ga to the Gbg dimer. On the basis of the three-
dimensional (3D) structure of the native heterotrimer,
Gia1b1g2, the first two WD40 repeats of Gb1 interact with
the N-terminal helix of Gia1, and it has been suggested
that this interaction confers a certain degree of specificity
to Ga-Gbg complex formation.29 Gb4 shares 96% amino
acid sequence homology with Gb1.
30 Gly53 and Lys89
are located within the first and second WD40 repeats,
respectively, of the b propeller, and according to high-reso-
lution structure analysis, Gly53 contacts one residue and
Lys89 contacts multiple residues within the N-terminal
helix of Gia1 (Figure S5).
29 Therefore, it is likely that the
interaction between Gb4 and Ga, but not the interaction
between Gb4 and Gg, is affected in both the p.Gly53Asp
and p.Lys89Glu Gb4 altered proteins. Although the dimer-
ization of Gb and Gg is obligatory in nature,31 the interac-
tion betweenGg and the altered forms of Gb4might render
a decrease in the functional wild-type Gb4-Gg dimer andrican Journal of Human Genetics 92, 422–430, March 7, 2013 427
thus exert a dominant-negative effect that abolishes rele-
vant GPCR signaling.
All of the individuals carrying the GNB4 c.158G>A
(p.Gly53Asp) or c.265A>G (p.Lys89Glu) mutation feature
a typical CMT phenotype that involves distal motor and
sensory function; however, the subject carrying the
c.265A>G (p.Lys89Glu) mutation had an earlier age of
onset, indicating that she was more severely affected.
The c.265A>G (p.Lys89Glu) mutation seemed to affect
Gb4 functioning more than the c.158G>A (p.Gly53Asp)
mutation in our small subject group. This is supported by
the 3D structure of the heterotrimeric Gia1b1g2. Whereas
Gly53 of Gb1 only interacts with Leu23 of Gia via van
der Waals interactions, Lys89 interacts with multiple resi-
dues, namely Gia via hydrogen bond with Ser16, via
a salt bridge with Asp20, and via van derWaals interactions
with Ile19 and Leu23 (Figure S5).29 Thus, Lys89 might be
more important than Gly53 in terms of the association
between subunits Ga and Gb, and this might therefore
cause the c.265A>G (p.Lys89Glu) mutation to produce a
more severe disease phenotype.
The diagnosis of DI-CMT in family 1 was based on the
NCVs and the sural nerve biopsies of subjects III:2 and
III:3, who had slow NCVs consistent mainly with
demyelinating neuropathy. Because NCV cannot faith-
fully reflect the underlying pathological changes, the full
pathological spectrum of Gb4-related neuropathy is yet
to be delineated. Given that Gb4 is highly expressed in
both axons and Schwann cells, mutations in GNB4 might
result in myelinopathy and/or axonopathy; this might
partially explain the phenotypic heterogeneity of the
family 1 individuals, in whom variable NCVs that blurred
the division between demyelinating and axonal CMTwere
documented.
In the family carrying theGNB4 c.158G>A (p.Gly53Asp)
mutation, men tended to be more severely affected than
women. If this proves to be true in a larger cohort, it will
imply that the Gb4 signal-transduction pathway might
be influenced by gender-preferential genes in the periph-
eral nerve tissues. One recent study uncovered 159 genes
that show male or female preference when expressed in
the brain.32 Our study suggests the interesting possibility
of identifying genes with sex-preferential expression in
peripheral nerves.
The fact that no significant difference in protein stability
exists between wild-type and altered forms of Gb4 suggests
that the pathomechanism of the GNB4 mutations is not
due to a haploinsufficiency of the Gb4 molecules. This
finding is consistent with the possible dominant-negative
mechanism. Because the stability of Gb4 is not affected by
the GNB4 mutations, the reduced Gb4 expression in the
sural nerves of the individuals with GNB4 mutation
suggests that the altered Gb4 might be toxic. If the Gb4-
related GPCR signaling function is vital to some cells, the
dominant-negative effect of the altered Gb4 could be lethal
or toxic to them. Alternatively, the altered Gb4 might have
gained a toxic function that is unrelated to the dominant-428 The American Journal of Human Genetics 92, 422–430, March 7negative effect. Such a toxic function could result in a
situation where cells expressing the most altered form of
Gb4 are likely to die first. In such a circumstance, the re-
maining cells in the sural nerves of these individuals would
be those with relatively lower Gb4 expression. This specu-
lation is supported by the lower cell and nerve-fiber densi-
ties in the sural nerve samples of the two individuals with
a GNB4 mutation than in those in the control samples
(Figure 3).
We have also screened for mutations in the genes encod-
ing the Gg subunits that are known to be expressed in the
peripheral nerves; these genes included GNG3 (MIM
608941), GNG4 (MIM 604388), GNG7 (MIM 604430),
GNG8, and GNG10 (MIM 604389) across 87 molecularly
unassigned and unrelated CMT individuals. So far, we
have not identified any relevant mutation in them (data
not shown). The possibility that other proteins that
interact with Gb4 might also be pivotal to the etiology of
some of these hereditary neuropathies cannot be ruled out.
In conclusion, our findings demonstrate that mutations
in GNB4 cause CMT, and this emphasizes the importance
of Gb4-related GPCR signaling to peripheral nerve func-
tioning in humans.Supplemental Data
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